Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

Clinical trial NCT01131325 · TERMINATED

Trial details

NCT number: NCT01131325
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 4
Study type: INTERVENTIONAL

CML Philadelphia Chromosome Positive (Ph+)Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

Start date: 2010-10-21
Primary completion: 2011-05-12
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.